Explore 3 Stock Ideas & Industry Insights Download Free Report

Actinogen Medical Limited

Company price
0.33 USD 0.00(0%)
Last update at 2026-11-19T21:00:00Z
VOLUME
500
Market Cap
113.49M

Momentum Score

…

Actinogen Medical Limited, a biotechnology company, develops therapies for neurological and neuropsychiatric diseases associated with dysregulated brain cortisol in Australia. It develops Xanamem, an oral medication and inhibitor of the 11ß-HSD1 enzyme that achieves target engagement in the brain for the treatment of Alzheimer's disease, major depressive disorder, fragile x syndrome, and other neurological diseases. The company was formerly known as Actinogen Limited and changed its name to Actinogen Medical Limited in November 2015. Actinogen Medical Limited was incorporated in 1999 and is based in Sydney, Australia.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.25
Low
0.33
High
52 Week Price Range
0.01
Low
0.04
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Actinogen Medical Limited is a clinical-stage biotech developing Xanamem, an oral 11β-HSD1 inhibitor designed to lower brain cortisol and address cognitive impairment such as Alzheimer’s disease and diabetes-related decline. Long-term upside may come from successful clinical data, regulatory progress or licensing, and expansion into related cognitive indications, which could make the company of interest to investors seeking exposure to a novel mechanism for dementia therapies.
Key risks are high clinical and regulatory uncertainty, limited revenues and the need for additional funding, low liquidity on OTC Pink, and competition from larger pharmaceutical companies.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.33
Dividend Yield
-
Revenue TTM
7.36M
Revenue Per Share
0.00
Gross Profit TTM
7.36M
Debt / Equity
0.18
ROE
-110.77%
Net Debt
-13.24M
ROCE
-82.89%
Diluted EPS TTM
-

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Income before tax -14.73M -22.98M -10.75M -9.50M -3.92M
Net income -14.73M -13.04M -10.75M -9.50M -3.92M
Selling general administrative 2.03M 1.73M 6.57M 4.56M 3.11M
Selling and marketing expenses 6.10M 5.50M - - -
Gross profit 5.49M 9.93M - - -
Reconciled depreciation 0.42M 0.42M 0.41M 0.40M 0.39M
Ebit -15.35M -13.26M -10.99M -9.53M -3.92M
Ebitda -15.01M -12.92M -10.33M -9.08M -3.51M
Depreciation and amortization 0.34M 0.33M - - -
Operating income -14.93M -12.84M -15.87M -13.17M -5.90M
Other operating expenses 20.42M 22.77M - - -
Interest expense 0.05M 0.02M 0.02M 0.02M 0.02M
Tax provision 0.00M 0.00M 0.00M 0.00M 0.00M
Interest income 0.69M 0.29M 0.37M 0.04M 0.03M
Net interest income 0.64M 0.27M 0.35M 0.02M 0.00M
Income tax expense - -9.93M - - -
Total revenue 5.49M 9.93M - - -
Total operating expenses 20.42M 22.77M - - -
Total other income expense net 0.20M -10.14M 4.77M 3.65M 1.98M
Net income from continuing ops -14.73M -13.04M -10.75M -9.50M -3.92M
Net income applicable to common shares - - -10.75M -9.50M -3.92M
Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Total assets 24.48M 21.31M 15.21M 23.31M 18.38M
Intangible assets 1.78M 2.09M 2.41M 2.72M 3.03M
Other current assets 0.13M 0.40M - - -
Total liab 6.15M 1.62M 1.80M 1.57M 0.92M
Total stockholder equity 18.34M 19.70M 13.41M 21.74M 17.46M
Other current liab 0.96M 0.70M 0.61M 0.50M 0.29M
Common stock 101.25M 100.02M 78.71M 76.94M 60.05M
Capital stock 101.25M 100.02M 78.71M 76.94M 60.05M
Retained earnings -96.47M -81.74M -68.69M -57.94M -48.44M
Other assets - - - - 0.04M
Cash 16.50M 9.45M 8.46M 16.37M 13.42M
Total current liabilities 5.96M 1.36M 1.80M 1.48M 0.76M
Net debt -13.24M -9.13M -8.37M -16.21M -13.19M
Short term debt 3.08M 0.06M 0.09M 0.08M 0.07M
Short long term debt 3.01M - - - -
Short long term debt total 3.26M 0.32M 0.09M 0.17M 0.24M
Other stockholder equity - - -1.55M -2.20M 1.74M
Property plant equipment - - 0.11M 0.17M 0.25M
Total current assets 22.43M 18.88M 12.69M 20.42M 15.06M
Net tangible assets - - 11.00M 19.02M 14.42M
Net receivables 5.80M 9.43M 4.23M 4.05M 1.63M
Inventory - -0.40M - - -
Accounts payable 1.93M 0.60M 1.10M 0.90M 0.39M
Accumulated other comprehensive income 13.56M 1.41M 3.39M 2.74M 5.85M
Non currrent assets other - - - - 0.04M
Non current assets total 2.05M 2.44M 2.52M 2.89M 3.32M
Capital lease obligations 0.26M 0.32M 0.09M 0.17M 0.24M
Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Investments -0.04M -0.01M -0.04M -0.00M -0.01M
Change to liabilities - - 0.25M 0.69M 0.11M
Total cashflows from investing activities -0.04M -0.01M -0.04M -0.00M -0.01M
Net borrowings 3.00M - -0.08M -0.07M -0.08M
Total cash from financing activities 14.65M 17.95M 0.82M 12.42M 10.11M
Change to operating activities - - 0.06M 0.03M -0.08M
Net income -14.73M -13.04M -10.75M -9.50M -3.92M
Change in cash 7.05M 0.99M -7.91M 2.95M 8.38M
Begin period cash flow 9.45M 8.46M 16.37M 13.42M 5.04M
End period cash flow 16.50M 9.45M 8.46M 16.37M 13.42M
Total cash from operating activities -7.56M -16.95M -8.70M -9.52M -1.72M
Issuance of capital stock 12.24M 19.11M 0.90M 13.32M 10.91M
Depreciation - 0.42M 0.41M 0.40M 0.39M
Change to account receivables 3.50M -5.20M -0.18M -2.41M 1.49M
Sale purchase of stock -0.53M -1.06M - -0.83M -0.72M
Other cashflows from financing activities -0.06M -0.09M -0.08M -0.07M -0.08M
Change to netincome - - 1.52M 1.27M 0.29M
Capital expenditures 0.04M 0.01M 0.04M 0.00M 0.01M
Change in working capital 3.54M -5.62M - - -
Other non cash items -11.09M 1.29M - - -
Free cash flow -7.59M -16.96M -0.04M -0.00M -0.01M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
ATGGF
Actinogen Medical Limited
-
-%
0.33 - - 15.41 18.91 177.64 -6.73
NVO
Novo Nordisk A/S
-1.06
2.73%
37.81 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc
-5.64
1.08%
515.02 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc
-
-%
920.69 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE
-
-%
965.00 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Actinogen Medical Limited

Actinogen Medical Limited, a biotechnology company, develops therapies for neurological and neuropsychiatric diseases associated with dysregulated brain cortisol in Australia. It develops Xanamem, an oral medication and inhibitor of the 11ß-HSD1 enzyme that achieves target engagement in the brain for the treatment of Alzheimer's disease, major depressive disorder, fragile x syndrome, and other neurological diseases. The company was formerly known as Actinogen Limited and changed its name to Actinogen Medical Limited in November 2015. Actinogen Medical Limited was incorporated in 1999 and is based in Sydney, Australia.

109 Pitt Street, Sydney, NSW, Australia, 2000

61 2 8964 7401

Name Title Year Born
Dr. Steven G. Gourlay ), FRACP, M.B.A., MBBS (M.D., Ph.D. MD, CEO & Director 1960
Mr. Jeff Carter BFinAdmin, MAppFin Chief Financial Officer 1958
Ms. Tamara Miller Sr. VP of Product Devel. NA
Prof. Paul Rolan D.C.P.S.A., F.F.P.M., F.R.A.C.P., M.B.B.S., M.D. Chief Medical Officer NA
Mr. Michael Roberts Head of Investor Relations & Corp. Communications NA
Ms. Therese Russell Head of People & Infrastructure NA
Dr. Christian Toouli Head of Bus. Devel. NA
Mr. Peter Gordon Webse B.Bus, FCIS, FCPA, FGIA, M.A.I.C.D., MAICD Company Sec. 1963
Dr. Steven G. Gourlay ), FRACP, M.B.A., MBBS (M.D., Ph.D. MD, CEO & Director 1959
Mr. William Edward Souter BCom, IPAA, LLB (Adel) Chief Financial Officer NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…